| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7cc315cc5a1fe3bf4c1730dd5a48c1f2 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
| filingDate |
2020-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f09403a5434d03d83cf94f454e0bbe2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96bcddd80b58ea751ccc11c221476509
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5cb5303cf5030ff47a32a70659ab3359
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06c5555328136a60c7c1325fb5e65123
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d80679302305f7f30821a50c3f4b7daf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0e66074a0e2fba6ca2bad3ac513d255
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cf0aa01215416cbd2f89c31c2e31857
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd238660f6fc2acbc99d25c75c4f3242 |
| publicationDate |
2020-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-111450097-A |
| titleOfInvention |
Application of Abl tyrosine kinase inhibitor in preparation of medicine for treating diseases caused by coronavirus |
| abstract |
The invention discloses the application of Abl tyrosine kinase inhibitor in preparing medicine for treating diseases caused by coronavirus. The invention also discloses the application of the Abl tyrosine kinase inhibitor in the preparation of a coronavirus inhibitor or a product for inhibiting the proliferation of the coronavirus. The present invention opens up new indications for Abl tyrosine kinase inhibitors including Gleevec, Dashina, Stacey, etc., because it is FDA-approved for the treatment of Philadelphia chromosome-positive myeloid/lymphoid The targeted small molecule drug for leukemia has completed a comprehensive safety evaluation, so it can be quickly used for the treatment of COVID-19 clinical trials. Abl tyrosine kinase inhibitors are expected to provide drug candidates for the COVID-19 epidemic and diseases caused by other coronaviruses, and have great application value for the treatment of SARS-CoV-2 coronaviruses and diseases caused by other coronaviruses. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114728006-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021223664-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113144194-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111991559-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111991559-B |
| priorityDate |
2020-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |